[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654680":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":36,"studyPopulation":37,"armGroups":38,"interventions":32,"overallOfficials":45,"centralContacts":49,"locations":57,"responsibleParty":85,"collaborators":32,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":32,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":32,"enrollmentInfo":96,"targetDuration":99,"studyType":100,"phases":32,"briefSummary":101,"conditions":102,"keywords":32,"overallStatus":106,"whyStopped":32,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Hacettepe University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Muscle Oxygen Saturation","Muscle oxygen saturation (SmO\\_2) will be measured continuously using Near-Infrared Spectroscopy (NIRS) (Train.Red FYER) on the intercostal, deltoid, and dominant quadriceps muscles. The primary parameter ΔSmO\\_2 max represents the difference between the peak SmO\\_2 during functional tasks (30-second sit-to-stand test, 4-meter gait speed test, and upper extremity assessment) and the baseline resting","baseline (1 day)",[14,17,20,23,26,29],{"measure":15,"description":16,"timeFrame":12},"functional capacity","30-Second Sit-to-Stand Test: Assesses functional lower-limb muscle strength and exercise capacity. The total number of completed full stand-ups from a chair (height 43.2 cm) within 30 seconds will be recorded.",{"measure":18,"description":19,"timeFrame":12},"Gait speed","4-Meter Gait Speed Test: Gait speed will be evaluated over a 4-meter course at normal walking pace. Gait speed is calculated in meters per second (m\u002Fs) by dividing 4 meters by the time taken",{"measure":21,"description":22,"timeFrame":12},"Peripheral Muscle Strength","Maximal isometric handgrip strength will be measured in kilograms (kg) using a digital hand dynamometer (Baseline BIMS). The highest value of three trials for both dominant and non-dominant hands will be recorded",{"measure":24,"description":25,"timeFrame":12},"pulmonary functions","Spirometry will be performed according to ATS\u002FERS guidelines. Values will be recorded.",{"measure":27,"description":28,"timeFrame":12},"Dyspnea and Fatigue Perception","Dyspnea will be evaluated using the Modified Medical Research Council (mMRC) scale (grades 0-4) and Visual Analog Scale (VAS, 0-10 cm). Fatigue perception will be assessed using the Modified Borg Scale (0-10) before and after functional tests.",{"measure":30,"description":31,"timeFrame":12},"Activities of Daily Living","Activities of daily living will be assessed using the London Chest Activity of Daily Living (LCADL) scale (score range 0-75).",null,{"allocation":32,"interventionModel":32,"interventionModelDescription":32,"primaryPurpose":32,"observationalModel":34,"timePerspective":35,"maskingInfo":32},"COHORT","CROSS_SECTIONAL","Chronic obstructive pulmonary disease (COPD) is characterized by recurrent acute exacerbations that negatively affect patients' quality of life and accelerate lung function decline. Severe exacerbations requiring hospitalization pose a significant mortality risk both during admission and in the following year.\n\nDuring acute exacerbations, maximal pressure generation by respiratory muscles declines, and respiratory muscle efficiency-particularly of the diaphragm-is significantly reduced. Acute dynamic hyperinflation further shortens the inspiratory muscles, leading to functional muscle weakness. Consequently, accessory respiratory muscles are recruited maximally, often causing notable alterations in chest-wall and abdominal kinematics. Due to the requirement of spending a higher proportion of their maximum capacity with each breath, these patients face an elevated risk of developing respiratory muscle fatigue. Exacerbations lead to severe hypoxemia caused by impaired pulmonary gas exchange, driven primarily by ventilation-perfusion mismatch and increased tissue oxygen consumption. Acute hypoxemia exacerbates muscle weakness and impairs skeletal muscle function. Even after discharge from respiratory intensive care units following severe exacerbations, persistent respiratory muscle dysfunction is observed in more than a third of patients, requiring additional care and rehabilitation.\n\nPhysiological factors such as impaired gas exchange, reduced perfusion, and systemic inflammation during exacerbations substantially impact muscle oxygenation. Reduced arterial oxygen content diminishes oxygen availability to peripheral tissues and muscles. Simultaneously, the metabolic demands of both respiratory and peripheral muscles increase due to the heightened work of breathing and systemic stress.\n\nThis study aims to investigate respiratory and peripheral muscle oxygenation in patients with AECOPD and stable COPD, evaluating underlying physiological changes and assessing the impact of exacerbations on muscle function and oxygenation dynamics.\n\nThe aim of study is to investigate respiratory and peripheral muscle oxygenation in patients with AECOPD.","The study population consists of adult patients aged 40 years and older diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD guidelines. The sample includes two distinct cohorts: patients admitted or presenting with an acute exacerbation of COPD (AECOPD), and patients in a clinically stable period (GOLD Grades 1-4) without exacerbations in the preceding 4 weeks.",[39,42],{"label":40,"type":32,"description":41,"interventionNames":32},"Acute copd patients","acute exacerbation of COPD",{"label":43,"type":32,"description":44,"interventionNames":32},"stable copd patients","clinically stable without any acute exacerbations for at least the past 4 weeks.",[46],{"name":47,"affiliation":5,"role":48},"Aynur Demirel","STUDY_DIRECTOR",[50,55],{"name":51,"role":52,"phone":53,"phoneExt":32,"email":54},"Aynur Demirel, PT, PhD, Assoc. Prof.","CONTACT","+90 554 529 5057","aynur.demirel@hacettepe.edu.tr",{"name":56,"role":52,"phone":32,"phoneExt":32,"email":32},"Alper kemal Gurbuz, PT, MSc.",[58],{"facility":5,"status":32,"city":59,"state":32,"zip":32,"country":60,"countryCode":32,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Ankara","Turkey (Türkiye)",{"type":62,"coordinates":63},"Point",[64,65],32.85427,39.91987,{"lat":65,"lon":64},[68,70,73,75,77,79,81,83],{"name":51,"role":52,"phone":69,"phoneExt":32,"email":54},"+905545295057",{"name":71,"role":72,"phone":32,"phoneExt":32,"email":32},"Alper Kemal Gurbuz, PT, MSc.","SUB_INVESTIGATOR",{"name":74,"role":72,"phone":32,"phoneExt":32,"email":32},"Irem Suzen, PT, MSc.",{"name":76,"role":72,"phone":32,"phoneExt":32,"email":32},"Hidaye Yamikan, PT, MSc.",{"name":78,"role":72,"phone":32,"phoneExt":32,"email":32},"Gulse Ozer, PT",{"name":80,"role":72,"phone":32,"phoneExt":32,"email":32},"Aysu Yalman, PT, MSc.",{"name":82,"role":72,"phone":32,"phoneExt":32,"email":32},"Oguz Karcioglu, MD, Assoc Prof.",{"name":51,"role":84,"phone":32,"phoneExt":32,"email":32},"PRINCIPAL_INVESTIGATOR",{"type":84,"investigatorFullName":47,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PT, PhD, Assoc. Prof.","100654680","muscle-oxygenation-in-patients-with-copd-exacerbation-100654680",false,"NCT07801547","Muscle Oxygenation in Patients With COPD Exacerbation","Evaluation of Respiratory and Peripheral Muscle Oxygenation in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\nAcute Exacerbation Group: 1. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) 2. Hospital admission or presentation due to an acute exacerbation of COPD 3. Age 40 years or older 4. Voluntary agreement to participate with signed written informed consent Clinically Stable Group: 1. Diagnosis of COPD (GOLD Stage 1, 2, 3, or 4) 2. Age 40 years or older 3. Clinically stable condition for at least the past 4 weeks without acute exacerbations 4. Voluntary agreement to participate with signed written informed consent\n\nExclusion Criteria: Acute Exacerbation Group: 1. Active participation in a formal pulmonary rehabilitation program 2. Co-existing neurological disorders 3. Heart failure classified as New York Heart Association (NYHA) Class III or IV 4. Unstable mental or cognitive status (Mini-Mental State Examination \\[MMSE\\] score ≤24) 5. History of surgical intervention within the past three months 6. Presence of malignant conditions .\n\nClinically Stable Group: 1. History of lung cancer, sarcoidosis, tuberculosis, and\u002For prior lung surgery 2. Known mental or cognitive impairment.","ALL","40 Years",{"count":97,"type":98},40,"ESTIMATED","1 Day","OBSERVATIONAL","Chronic obstructive pulmonary disease (COPD) is often complicated by acute exacerbations, which lead to functional impairments, increased dyspnea, and a rapid decline in lung function. During an exacerbation, impaired pulmonary gas exchange, systemic inflammation, and increased work of breathing significantly alter oxygen availability and metabolic demand in skeletal muscles. The aim of this study is to evaluate and compare respiratory and peripheral muscle oxygenation in patients with acute exacerbation of COPD (AECOPD) and patients with clinically stable COPD. By examining these physiological changes, the study seeks to determine the impact of exacerbations on muscle function and oxygenation efficiency",[103,104,105],"COPD (Chronic Obstructive Pulmonary Disease)","Acute Exacerbation Chronic Obstructive Pulmonary Disease","Muscle Oxygenation","NOT_YET_RECRUITING","2026-08-28",{"date":109,"type":110},"2026-09-03","ACTUAL",{"date":112,"type":98},"2026-08-30",{"date":114,"type":98},"2028-02-05",{"name":5,"class":6},1]